BR112012007332A2 - nova composição farmacêutica que compreende um macrólido imunossupressor - Google Patents

nova composição farmacêutica que compreende um macrólido imunossupressor

Info

Publication number
BR112012007332A2
BR112012007332A2 BR112012007332A BR112012007332A BR112012007332A2 BR 112012007332 A2 BR112012007332 A2 BR 112012007332A2 BR 112012007332 A BR112012007332 A BR 112012007332A BR 112012007332 A BR112012007332 A BR 112012007332A BR 112012007332 A2 BR112012007332 A2 BR 112012007332A2
Authority
BR
Brazil
Prior art keywords
compositions
pharmaceutical composition
new pharmaceutical
immunosuppressive
immunosuppressive macrolide
Prior art date
Application number
BR112012007332A
Other languages
English (en)
Other versions
BR112012007332B1 (pt
Inventor
Alexandra Sabine Bärbel Göbel
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of BR112012007332A2 publication Critical patent/BR112012007332A2/pt
Publication of BR112012007332B1 publication Critical patent/BR112012007332B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4055—Concentrating samples by solubility techniques
    • G01N2001/4061—Solvent extraction

Abstract

resumo da patente de invenção para: nova composição farmacêutica que compreende um macrólido imunossupressor. a invenção descreve novas composições farmacêuticas de macrólidos imunossupressores. as composições compreendem um componente hidrofílico, um componente lipofílico, e um componente antifílico. de preferência, as composições são formuladas como microemulsões líquidas. além disso, a invenção proporciona utilizações de tais composições, tais como para o tratamento tópico de doenças inflamátorias e autoimunes. métodos para preparar as composições são também fornecidos.
BR112012007332-0A 2009-10-08 2010-10-07 Composição farmacêutica que compreende um macrólido imunossupressor e seu método de preparo BR112012007332B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09012724.2 2009-10-08
EP09012724A EP2308468A1 (en) 2009-10-08 2009-10-08 Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
PCT/EP2010/064965 WO2011042485A1 (en) 2009-10-08 2010-10-07 Novel pharmaceutical composition comprising a macrolide immunosuppressant drug

Publications (2)

Publication Number Publication Date
BR112012007332A2 true BR112012007332A2 (pt) 2016-10-04
BR112012007332B1 BR112012007332B1 (pt) 2021-07-13

Family

ID=41435414

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012007332-0A BR112012007332B1 (pt) 2009-10-08 2010-10-07 Composição farmacêutica que compreende um macrólido imunossupressor e seu método de preparo

Country Status (12)

Country Link
US (1) US8574562B2 (pt)
EP (2) EP2308468A1 (pt)
JP (1) JP5764792B2 (pt)
KR (1) KR101790257B1 (pt)
CN (1) CN102510752B (pt)
AU (1) AU2010305404B2 (pt)
BR (1) BR112012007332B1 (pt)
CA (1) CA2774720C (pt)
ES (1) ES2552803T3 (pt)
IN (1) IN2012DN01559A (pt)
MX (1) MX2012003800A (pt)
WO (1) WO2011042485A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
AU2012274367A1 (en) * 2011-06-23 2014-01-23 Santen Pharmaceutical Co., Ltd. Ophthalmic solution containing hyaluronic acid or salt thereof and propylene glycol
DK2948134T3 (da) 2013-01-24 2020-06-02 Palvella Therapeutics Inc Sammensætninger til transdermal indgivelse af mtor-inhibitorer
CN103830178B (zh) * 2014-03-18 2017-01-11 深圳劲创生物技术有限公司 一种蒜氨酸微乳及其制备方法和应用
KR20180032652A (ko) 2015-08-11 2018-03-30 아이씨유 메디슨스 비.브이. 생체활성 친유성 화합물을 갖는 peg화된 지질 나노입자
CA3020157C (en) 2016-04-04 2024-01-16 Drug Delivery Solutions Limited Topical composition comprising tacrolimus
US20200323793A1 (en) * 2016-06-03 2020-10-15 Avexxin As Combination therapy comprising a polyunsaturated ketone and a calcineurin inhibitor
CN106074386A (zh) * 2016-08-31 2016-11-09 佛山市弘泰药物研发有限公司 一种依维莫司自微乳制剂及其制备方法
AU2017329957B2 (en) 2016-09-21 2020-05-07 Avexxin As Pharmaceutical composition
US10722499B2 (en) 2017-01-06 2020-07-28 Palvella Therapeutics, Inc. Anyhydrous compositions of mTOR inhibitors and methods of use
EP3691654A4 (en) 2017-09-25 2021-11-24 Surface Pharmaceuticals, Inc. OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF EYE SURFACE DISEASES
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
WO2019233722A1 (en) 2018-06-08 2019-12-12 Almirall, S.A. Pharmaceutical composition comprising tacrolimus
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
TWI769745B (zh) * 2021-03-19 2022-07-01 國泰醫療財團法人國泰綜合醫院 醫藥組成物與製藥用途
BE1030538B1 (nl) 2022-05-18 2023-12-19 Bogaert Gina Van Liposomaal preparaat met ingekapselde hormonen, werkwijze voor de productie en gebruik ervan

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2212061B (en) * 1987-11-09 1991-08-28 Sandoz Ltd Topical compositions comprising 11,28-dioxa-4-azatricyclo [22.3.1.0(4,9)] octacos-18-ene derivatives
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
GB2315216B (en) * 1993-10-05 1998-10-14 Ciba Geigy Ag Microemulsion preconcentrates comprising FK506 or 33-epi-chloro-33-desoxy-ascomycin
ATE299017T1 (de) * 1994-10-26 2005-07-15 Novartis Pharma Gmbh Arzneimittel
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
IL161588A0 (en) * 2001-11-01 2004-09-27 Yissum Res Dev Co Method and composition for dry eye treatment
EP1455810B1 (de) * 2001-12-14 2007-06-13 Jagotec Ag Arzneiformulierung enthaltend ciclosporin und deren verwendung
JP2008506656A (ja) * 2004-07-16 2008-03-06 ノバルティス アクチエンゲゼルシャフト 皮膚透過性の亢進のためのステロイドの使用
CA2586074C (en) * 2004-11-09 2013-07-23 Novagali Pharma Sa Ophthalmic oil-in-water type emulsion with stable positive zeta potential
KR100678829B1 (ko) * 2004-12-06 2007-02-05 한미약품 주식회사 타크로리무스의 경구용 마이크로에멀젼 조성물
WO2006123354A2 (en) * 2005-02-02 2006-11-23 Mega Lifesciences Pvt. Ltd. Oral pharmaceutical composition
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
DK1848431T3 (en) * 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS

Also Published As

Publication number Publication date
KR20120093865A (ko) 2012-08-23
CA2774720C (en) 2017-05-23
KR101790257B1 (ko) 2017-10-26
US20120184511A1 (en) 2012-07-19
EP2485714B1 (en) 2015-09-09
ES2552803T3 (es) 2015-12-02
EP2485714A1 (en) 2012-08-15
US8574562B2 (en) 2013-11-05
JP2013507337A (ja) 2013-03-04
BR112012007332B1 (pt) 2021-07-13
EP2308468A1 (en) 2011-04-13
WO2011042485A1 (en) 2011-04-14
JP5764792B2 (ja) 2015-08-19
MX2012003800A (es) 2012-06-28
IN2012DN01559A (pt) 2015-06-05
AU2010305404A1 (en) 2012-03-08
AU2010305404B2 (en) 2015-04-02
CN102510752B (zh) 2015-08-05
CN102510752A (zh) 2012-06-20
CA2774720A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
BR112012007332A2 (pt) nova composição farmacêutica que compreende um macrólido imunossupressor
UY32728A (es) Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia
CR11455A (es) Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades
BR112016004023A2 (pt) Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
CR11731A (es) Composiciones y procedimientos para su preparación y uso
EA201070421A1 (ru) Микрорибонуклеиновые кислоты
CL2007003765A1 (es) Compuestos derivados de 2-oxo-4-hidroxi-benzotiazol; procesode preparacion; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, bronquitis, asma y bronquiectasias.
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
CL2008000307A1 (es) Compuestos derivados de cromen-2-ona sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como ateroesclerosis, asma, rinitis alergica y epoc.
CL2008001632A1 (es) Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma.
ECSP099061A (es) Moduladores de benzofuro- y benzotienopirimidina
CL2008000434A1 (es) Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
BRPI0909040A8 (pt) Derivados de azetidina e ciclobutano, seus usos, e composição
BR112014022708A8 (pt) uso de uma proteína ligante de neurotrofina p75ntr, uso de uma molécula de ácido nucleico, uso de um vetor de expressão replicável, célula hospedeira, composição farmacêutica e kit
EA201300987A1 (ru) Фармацевтические композиции, включающие метформин и ингибитор dpp-4 или ингибитор sglt-2
BRPI0915680A2 (pt) miméticos de glicocorticoide, métodos de prepará-los, composições farmacêuticas, e usos dos mesmos
CL2008003549A1 (es) Compuestos derivados de glucocorticoides; procedimientos de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades a la piel como eczema, afecciones a la nariz, garganta y pulmones como rinitis o asma, enfermedades inflamatorias del intestino, oculares y autoinmunes.
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
BR112012023950A2 (pt) formas cristalinas de um macrolídeo, e usos dos mesmos
CL2007001648A1 (es) Compuesto derivado de leptomicina; conjugado que comprende agente de unión a células unido a uno o mas de dichos derivados; composiciones farmacéuticas que comprenden dicho derivado o conjugado; util en el tratamiento del cancer; proceso de preparacion de un compuesto o de un conjugado de un derivado de leptomicina.
BRPI0606132A2 (pt) formas cristalinas de docetaxel e processos para seu preparo
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
CY1114960T1 (el) Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B25A Requested transfer of rights approved

Owner name: REINARD NEUBERT (DE) ; JOHANNES WOHLRAB (DE)

B25A Requested transfer of rights approved

Owner name: SKINOMICS GMBH (DE)

B25A Requested transfer of rights approved

Owner name: BAY PHARMA GMBH (DE)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/10/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.